NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.0062 (+4.3145%)

Stability Price

Undervalued by 96.93%

Company Metrics

  • P/E 0
  • P/S 3.8661
  • P/B 47.9000
  • EPS -0.3170
  • Cash ROIC -2,078.99%
  • Cash Ratio 1.62
  • Dividend 0 / N/A %
  • Avg. Vol. 318,880.00
  • Shares 49.63M
  • Market Cap. 13.05M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


NovaBay Pharmaceuticals, Inc. Short Interest Update
Money Flow Index - 18 hours ago
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has witnessed a drop of 33.6% or 420,549 shares in its short figure. The short interest diminution took it from 1,251,663 on October 30,2015 to 831,114 on November 13,2015.
NovaBay Pharmaceuticals Sees Significant Decline in Short Interest (NBY) - Dakota Financial News
Maxim Group Cuts NovaBay Pharmaceuticals Price Target to $1.00 (NBY) - Voice Chronicle
NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
NovaBay Pharma restructures to boost commercialization of Avenova
Seeking Alpha - Nov 19, 2015
With the aim of focusing on the ramping up Avenova sales, NovaBay Pharmaceuticals (NBY +1.7%) Chairman Mark Sieczkarek assumes the role of interim President & CEO replacing former President & CEO and founder Ron Najafi, Ph.
NovaBay Pharmaceuticals Announces Restructuring to Focus on Avenova ... - Business Wire (press release)
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Announces Restructuring ... - The Wall Street Transcript
Healthcare Stocks Shaking Down: NovaBay Pharmaceuticals, (NYSEMKT:NBY ...
Benchmark Monitor - 14 hours ago
On 19 November, NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) reported total net sales of $1.2 million for the third quarter of 2015, up from $152,000 for the third quarter of 2014.
Novabay Pharmaceuticals Inc (NYSEMKT:NBY) Had Its PT Decreased by 50.00 % at ...
OctaFinance.com - Nov 20, 2015
In a report revealed by Maxim Group on Friday morning, Novabay Pharmaceuticals Inc (NYSEMKT:NBY) had its target lowered to $1.00.
Company Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) Rally 11.06%
Insider Trading Report - Nov 15, 2015
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) appreciated by 11.06% during the past week but lost 39.42% on a 4-week basis.
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Reschedules Third ... - The Wall Street Transcript
NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call to ... - Business Wire (press release)
Company Shares of NovaBay Pharmaceuticals, Inc. Drops by -3.92%
News Watch International - Aug 3, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has lost 3.92% during the past week and dropped 10.74% in the last 4 weeks.
Zacks Short Term Rating on NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY)
Insider Trading Report - Nov 10, 2015
As many as 1 brokerage firms have rated NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) at 1. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term.
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) reported sales of $1.2 million and ...
Stock Transcript - Nov 20, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) reported total net sales of $1.2 million for the third quarter of 2015, up from $152,000 for the third quarter of 2014.
NovaBay Pharmaceuticals Given New $1.00 Price Target at Maxim Group (NBY) - Dakota Financial News
NovaBay Pharmaceuticals (NBY) Releases Earnings Results, Hits Expectations - WKRB News
Short Interest Update on NovaBay Pharmaceuticals, Inc.
Money Flow Index - Oct 27, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), A reduction of 295,994 shares or 15.4% was observed in the short interest of NovaBay Pharmaceuticals The interest on October 15,2015 came in at 1,624,864 shares and as per the average daily trading of ...
Biotech Stocks Attracting Some Extra Attention:NovaBay Pharmaceuticals, Inc ... - Wall Street Observer
Short Interest in NovaBay Pharmaceuticals Drops By 15.4% (NBY) - Dakota Financial News